Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
← catalyst calendarNCT05046613 · readout in 1,173 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With PPD, Part of Thermo Fisher Scientific.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
780estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-23 | actual | When the study began enrolling |
| Primary completion | 2029-11-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2034-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2021-09-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Migraine
Interventions
- Other: Rimegepant
- Other: Not taking Rimegepant
Primary outcome
what the primary-completion date above is the date OFMajor congenital malformation (birth defect)
measured Annually beginning April 2022
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed